Evicenter
P&T meetings

Bezuclastinib

Nonadvanced systemic mastocytosis

Manufacturer
Cogent Biosciences
Regulatory submission
NDA submitted December 2025
Last updated
62 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Cytoreductive therapies

1 evidence topic · 1 source

Selected refractory mediator symptoms or bone disease

“severe, refractory mediator symptoms or bone disease” (opens the source at this quote in a new tab)

“cladribine” (opens the source at this quote in a new tab)

“peginterferon alfa-2a” (opens the source at this quote in a new tab)